Drug Trial Radar · NCT07223632
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1
Actual
Start
May 13, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an 'N of 1', open-label, single center study to evaluate the safety of therapy with VCA-894A, an ASO designed to rescue and restore the activity of IGHMBP2, when administered by intrathecal injection.
Conditions
- Charcot Marie Tooth Disease (CMT)
- Neuromuscular Diseases (NMD)
Interventions
VCA-894ADrug
intrathecal antisense oligonucleotide injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of safety of therapy with VCA-894A when administered via intrathecal injection, as measured by the incidence of adverse events.Time frame: 631 days
- Assessment of CMT2S symptoms following chronic administration of intrathecal VCA-894A, as determined by the change in the Revised Upper Limb Module for Spinal Muscular Atrophy (RULM).Time frame: 631 days
- Assessment of CMT2S symptoms following chronic administration of intrathecal VCA-894A, as determined by the change in the Hammersmith Functional Motor Scale - Expanded (HFMSE).Time frame: 631 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanda Investigational Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.